 |
 |
 |
|
 |
|
 |
|
 |
 Stress, Mood, and Behavioral Disorders Neuropsychiatric Symptoms in Huntington’s Disease. Irritability, anxiety, and aggression are commonly observed in a high percentage of HD patients. These neuropsychiatric manifestations of HD are difficult to treat with existing pharmacologic and behavioral approaches and have major effects on the quality of life of HD subjects and their families. Post-Traumatic Stress Disorder (PTSD) is the most rapidly growing psychiatric diagnosis in the United States and a major issue for military medicine. Current treatments are repurposed drugs that are minimally effective. Intermittent Explosive Disorder severely impacts quality of life and poses substantial risk to patients. Current estimates indicate up to 6% lifetime prevalence in the US alone. There are currently no approved treatments. Anger/Aggression/Impulse Control Disorders are common co-morbidities impacting therapeutic response in multiple indications, including TBI, ADHD PTSD, and personality disorders. There are currently no approved treatments. Major Depression and Treatment Resistant Depression (TRD). Some 50% of patients do not respond to current drug therapies; A novel, non-monoamine mechanism of action provides differentiation and an opportunity to address TRD. |
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications. |
|